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Suspected acute hemolytic transfusion 
reaction mediated by anti-Dia
A. Bennett, R.K. Boyapati, and F.S. Hong
Case report
Anti-Dia can mediate hemolytic disease of the fetus and newborn, 
but it is unclear if it can cause hemolytic transfusion reactions 
(HTRs). To date, there has only been one report of a possible 
immediate HTR attributed to anti-Dia. Our case report details an 
immediate HTR due to anti-Dia in a patient with pre-existing liver 
failure. This reaction triggered multi-organ failure, and the patient 
subsequently died. This case also highlights the importance of 
considering HTRs even when routine antibody screening has 
been unremarkable, particularly when electronic crossmatch is 
used, because of the potential for an alloantibody against a low-
prevalence antigen. Immunohematology 2015;31:163–165.
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A 59-year-old Chilean woman, 18 years post-orthotopic 
liver transplant for primary biliary cirrhosis, was admitted to 
hospital with primary biliary cirrhosis recurrence manifest 
with decompensated liver failure (ascites, encephalopathy, 
jaundice, renal impairment, and coagulopathy), pancytopenia, 
and fever, for which she was empirically started on ceftriaxone 
and ampicillin. Her other medications included spironolactone, 
furosemide, mycophenolate mofetil, tacrolimus, lactulose, and 
ursodeoxycholic acid; azathioprine had recently been ceased 
because of pancytopenia.
Because of significant anemia (hemoglobin 6.2 g/dL), 
blood transfusion was arranged. Group and screen procedures 
revealed that the patient was blood group A, D+; no 
alloantibodies were identified on a standard three-cell 
screening panel (Abtectcell III 0.8%; CSL Biotherapies, 
Melbourne, Australia) using column agglutination technology 
(Diamed-ID gel card method; Diamed, Cressier, Switzerland). 
One unit of group A, D+, red blood cells (RBCs) was issued 
using electronic crossmatch.
Less than 1 hour into the RBC transfusion, the patient 
developed chills, fever (39.0°C), tachycardia (115 beats/min), 
hypertension (blood pressure 160/70 mmHg) and a non-
blanching purpuric rash over her trunk and legs, prompting 
immediate cessation of the transfusion. The fever subsequently 
resolved. Twelve hours later, the rash had worsened (fulminant 
retiform purpura) and was newly associated with tongue 
swelling. The patient was transferred to the intensive care 
unit for intubation, nebulized adrenaline, inotropic support, 
and continuous venovenous hemodialysis because of the 
development of anuria. Coagulation parameters worsened, 
including hypofibrinogenemia refractory to cryoprecipitate 
and fresh frozen plasma transfusions. Pertinent investigation 
results are listed in Table 1. Creatinine kinase peaked at 20,325 
U/L (reference interval 20–180 U/L) and haptoglobin fell to 
<10 mg/dL (reference interval 50–330 mg/dL). As part of the 
evaluation of the suspected transfusion reaction, the direct 
antiglobulin test (DAT) was performed post-transfusion using 
the gel card method (Diamed) with a reaction score of 2 (scale 
0–4) in a pre-transfusion sample but 3 (scale 0–4) in a post-
transfusion sample.
Results
Following the transfusion reaction, an indirect antiglobulin 
test (IAT) crossmatch between donor and recipient was found 
to be incompatible (reaction score 12 [scale 0–12]), suggestive 
of an alloantibody in the patient serum. Testing of a pre-
transfusion sample with a 3-cell antibody screening panel and 
an 11-cell antibody identification panel (Phenocell B 0.8%; 
CSL Biotherapies) was negative, suggesting an alloantibody 
against a low-prevalence antigen. Further testing of the pre-
transfusion sample with a different 11-cell antigen panel 
(Phenocell C 0.8%, CSL Biotherapies) revealed the presence of 
possible anti-Dia. This result was confirmed by the Australian 
Red Cross Blood Service Red Cell Reference Laboratory, 
which also performed phenotyping of the recipient (using pre-
transfusion sample) and donor. The recipient’s phenotype was 
group A; DCce; K–; Fy(a–b+); Jk(a+b–); M+N+S–s+; Di(a–). 
Anti-Dia was detected in pre- and post-transfusion samples 
by multiple methods, including saline 22°C and 37°C, low-
ionic IAT, polyethylene glycol-IAT, low-ionic-strength saline/
Coombs card (Diamed), and enzymes. No other alloantibodies 
were detected. Recipient DAT was positive because of IgG, as 
detected by tube, score 3 (scale 0–4) and Bio-Rad DAT card, 
score 10 (scale 0–12) (DC-Screening II, Diamed). The donor’s 
phenotype was group A, DcE; K–k+; Fy(a+b–); Jk(a+b+); 
M+N+S–s+; Di(a+b+); DAT was negative.
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The patient received five further RBC transfusions, of which 
the initial two were released following electronic crossmatch, 
with the remaining three units released after IAT crossmatch 
once anti-Dia was suspected. Of the two units released 
following electronic crossmatch, one donor was confirmed to 
be Di(a–). The other donor did not return so phenotyping was 
not possible. It was also not possible to retrospectively perform 
a crossmatch of this donor’s RBC unit with patient plasma due 
to donor sample unavailability. Donor typing had not been 
performed on the three IAT-crossmatched units because their 
compatibility indicated that they were antigen negative. None 
of these RBC transfusions caused any adverse effects. Despite 
active management, the patient continued to deteriorate and 
died 6 days following the implicated transfusion. The cause 
of death was thought to be underlying liver failure, with the 
hemolytic transfusion reaction (HTR) as an acute precipitant 
of multi-organ failure.
Discussion
This episode most likely represents an immediate 
acute HTR due to anti-Dia, based on clinical presentation 
and laboratory parameters such as increasing lactate 
dehydrogenase, falling haptoglobin, and positive DAT. 
Reticulocyte count remained inappropriately low due to bone 
marrow suppression secondary to liver failure and recent 
azathioprine. The hemolytic reaction was further complicated 
by progressive disseminated intravascular coagulation and 
worsening renal failure, which were likely contributed to by 
underlying liver failure. As anti-Dia was the only antibody 
present, we concluded that the HTR was triggered by anti-Dia. 
Other explanations for the reaction were considered but 
thought less likely. For example, sepsis was unlikely given 
that multiple blood cultures from the patient and returned 
donor unit were negative for bacterial growth. Polymerase 
chain reaction for cytomegalovirus, varicella zoster virus, and 
herpes simplex virus were negative. Epstein–Barr virus IgM 
was negative. Anaphylactic reaction was also unlikely given 
the lack of improvement to adrenaline, the patient’s normal 
serum IgA levels, and the fact that prior transfusions were not 
associated with reactions.
This patient may have been sensitized to Dia during 
pregnancy [noting her partner is also of South American 
origin, and therefore may be Di(a+)] or previous blood 
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Table 1. Investigation results 
Day 0* Day 1 post-transfusion Day 2 post-transfusion Day 3 post-transfusion Reference interval
Hemoglobin (g/dL) 6.5 6.3 8.1 6.8 11.5–16.5
Lactate dehydrogenase 
(IU/L)
166 751 1693 — 135–214
Haptoglobin (mg/dL) 50† <10 <10 — 50–330
Reticulocytes (× 109/L) 20‡ 49 55 — 20–100
Direct antiglobulin test 
(IgG only)
2 3 — — Scale 0–4
Prothrombin time (s) 29 33 38 35 11–15
Activated partial 
thromboplastin time (s)
43 73 55 48 22–38
Fibrinogen Clauss (g/L) 1.7 1.0 <0.8 <0.8 2.0–4.0
Creatine kinase (U/L) 46§ 13,073 20,325 6673 20–180
Creatinine (mg/dL) 4.0 5.6 3.2¶ 2.0¶ 0.7–1.2
Bilirubin (mg/dL) 35.1 36.8 33.4 29.2 <1.1
Blood film Hypochromia with target 




Target cells, nucleated 
red blood cells, 
crenated cells, and 
schistocytes
Numerous nucleated 




RBC = red blood cell.




¶Patient on continuous venovenous hemodialysis.
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Hemolytic reaction due to anti-Dia
transfusions (e.g., as part of the prior liver transplantation 
procedure). Given the known pattern of Dia antigen expression 
in the body, it is unlikely that the transplanted liver in itself 
was a stimulus. There was no history of hemolytic disease 
of the fetus and newborn (HDFN) complicating the patient’s 
prior pregnancies.
The Diego blood group was first discovered in 1955, 
during investigations into a case of HDFN.1,2 Dia is mostly 
found in Mongolian populations, 36 percent of South 
American Indians, approximately 12 percent of Japanese 
and Chinese individuals, and a smaller proportion of Polish 
people.3–6 Most Caucasians are Di(a–b+). The Diego protein 
(also known as the SLC4A1 protein) is expressed on RBCs 
and in renal tubules, where it plays an important role in RBC 
membrane stability and anion exchange. Anti-Dia is known 
to mediate HDFN.4,6–8 To our knowledge, there has only been 
one other report of an immediate HTR attributed to anti-Dia.9 
In that case, the patient developed fevers, flank pain, and 
hemoglobinuria, which self-resolved. There has also been one 
case report of a delayed transfusion reaction due to multiple 
alloantibodies (including antibodies to E, Jka, Dia, Fyb, and 
S), although in that case, the clinical presentation could not 
be attributed to anti-Dia alone, because of the presence of the 
other alloantibodies.10
Because the standard commercial RBC antibody testing 
panels in Australia are prepared from donor RBCs, and 
the donors are predominantly Caucasian, antibodies to 
low-prevalence antigens such as Dia may not be detected 
during routine screening. In combination with electronic 
crossmatching, this can expose patients to risks of hemolysis 
from undetected alloantibodies. It is important, therefore, for 
clinicians and laboratory scientists to consider the possibility 
of HTR even when no antibodies are detected on screening 
and the RBCs are issued using electronic crossmatch.
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